| Christine Marie Beran, LPN | |
|
31 Orlando Ave, Pittsfield, MA 01201-2223 | |
| (413) 329-5599 | |
| Not Available |
| Full Name | Christine Marie Beran |
|---|---|
| Gender | Female |
| Speciality | Licensed Vocational Nurse |
| Location | 31 Orlando Ave, Pittsfield, Massachusetts |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205348422 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164X00000X | Licensed Vocational Nurse | LN49685 (Massachusetts) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Christine Marie Beran, LPN 5 Cornell Ln, Peru, MA 01235-9215 Ph: (413) 344-5108 | Christine Marie Beran, LPN 31 Orlando Ave, Pittsfield, MA 01201-2223 Ph: (413) 329-5599 |
News Archive
Sysmex, a global leader in medical diagnostic testing equipment and information systems technology, today announced a three-year, dual source urinalysis contract agreement with Amerinet. Amerinet members have immediate purchasing/leasing access to Sysmex automated urine particle analyzers, reagents, controls, and service.
Eli Lilly and Company as part of a continued commitment to innovation in the area of diabetes, announced today the creation of a strategic relationship with EyeTel Imaging, Inc. to improve screening and detection of diabetic retinopathy, one of the potentially devastating diabetic microvascular complications. The agreement, which expands the relationship between the two companies, will provide EyeTel with on-going operational support from Lilly, allowing EyeTel to provide primary care physicians access to state-of-the-art patient risk assessment tools and education programs.
Migraine patients who took 100 mg three times a day of CoQ10—which acts as the body's energy producer—had fewer attacks in three months than those who took a placebo. The participants taking CoQ10 also had fewer days with a headache and fewer days with nausea.
InspireMD Ltd., a medical device company engaged in the development and commercialization of the mesh based MGuard(TM) stent systems, is proud to report that mesh-based protection, is now recommended for use in the new Guidelines of the Task force of Myocardial Revascularization of the European Society of Cardiology (ESC). According to the latest European Society of Cardiology Guidelines, published at the ESC Congress last week, "Mesh-based protection may be considered for PCI of highly thrombotic or SVG lesions" - it has received a class IIb recommendation.
Academics in the University of Surrey's Department of Chemistry have developed a new diagnostic test for cocaine and benzoylecgonine (the main metabolite for cocaine) in urine and oral fluid.
› Verified 9 days ago